A5042778405- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Hematological disorders and diagnostics
- Inflammatory Biomarkers in Disease Prognosis
- Ferroptosis and cancer prognosis
- Cutaneous lymphoproliferative disorders research
- Neuroblastoma Research and Treatments
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Immunodeficiency and Autoimmune Disorders
- Epigenetics and DNA Methylation
- CNS Lymphoma Diagnosis and Treatment
- Urticaria and Related Conditions
- Head and Neck Cancer Studies
- Acute Lymphoblastic Leukemia research
- Thyroid Disorders and Treatments
- COVID-19 Clinical Research Studies
- Electrolyte and hormonal disorders
- Myasthenia Gravis and Thymoma
- Sarcoma Diagnosis and Treatment
- COVID-19 and healthcare impacts
Ministry of Health of the Russian Federation
2021-2023
Rostov Research Institute of Oncology
2021-2022
Purpose : to study the level of LAG-3 expression on B-lymphocytes and feasibility using it as a marker for predicting response therapy in patients with chronic lymphocytic leukemia (CLL). Material Methods . The included 40 newly diagnosed CLL. All were divided into two groups: group I: Binet stage A, who did not receive II: C, received immunochemotherapy RB FCR regimes. According treatment regimen hematological therapy, 4 subgroups distinguished: IIA-RB, IIA-FCR, IIB-RB, IIB-FCR. control...
Aim. To create a collection of samples blood components patients with multiple myeloma for potential fundamental and applied biomedical research. Material methods . The material was collected according to the developed algorithm, including clinical information, biological material, sample preparation, quality control storage in biobank National Medical Research Center Oncology. Results. As August 2021, cryostorage Oncology contains 175 serum, plasma mononuclear cell fraction myeloma. Samples...
Introduction . Multiple myeloma (MM) accounts for 1% of all cancers and about 10% hematological malignancies. Although there are many types current therapeutic approaches, MM still remains an incurable disease, which points to the need improvement management patients with this disease in real-world clinical settings. Aim To analyze actual practice treating Russian multiple (MM). Materials methods A multicenter observational retrospective study was conducted. The final analysis included data...
Background. Recently, studies have been conducted all over the world to study role of immune checkpoints in pathogenesis chronic lymphocytic leukemia (CLL) and possibility their use as prognostic markers. Of greatest interest are PD-1 (programmed cell death-1) LAG-3 protein (lymphocyte-activation gene 3). Aim. To features (CD279) (CD223) expression on blood B-cells CLL patients early markers for predicting hematological response therapy. Materials methods. The 30 with stage C according Binet...
With a frequency of 2.2 cases per 100,000 population in Russia, Hodgkin's lymphoma (HL) is one the most common malignant neoplasms young people. In connection with predominant spread HL among people, issue effective treatment various forms remains relevant. Currently, 70-90 % patients who have received standard chemotherapy or chemoradiotherapy long period remission. However, 10 progressive course, can`t achieve response, and 30 subsequently recur. The approach treating recurrent and/or...
e19580 Background: Many studies have been devoted to the molecular profile of diffuse large B-cell lymphoma; however, a clear and genetic picture primary mediastinal lymphoma (PMBLC) has not yet described. Studies reported various signaling pathways involved in PMBCL pathogenesis, with best known JAK-STAT NF-kB. This study was aimed at detection previously undescribed mutations, as well identification that may be interest search for new therapeutic targets PMBCL. Methods: Tumor biopsy...
e15009 Background: Multiple myeloma (MM) is a B-cell malignancy resulting from the abnormal proliferation of neoplastic plasma cells that produce monoclonal immunoglobulin (Ig). The high variability course this disease, its genetic clonal heterogeneity, due to chromosomal deletions, hyperploidy involving an odd number chromosomes, as well aberrations, such rearrangement Ig heavy chain gene loci. Since available biomarkers do not take into account feature MM, there need develop more advanced...
Introduction. Primary mediastinal large B-cell lymphoma is an aggressive variant of characterized by genetic heterogeneity. First-time therapy for primary usually includes immunochemotherapy. However, a substantial proportion patients do not respond to this therapy. Objective – analyze clinical characteristics refractory taking into account the results targeted next-generation sequencing (NGS). Materials and methods. A 22‑year-old patient with who had responded immunochemotherapy was tested...
Diffuse large B-cell lymphoma (DLBCL) is the most common variant of non-Hodgkins and accounts for 3060% all lymphomas, with increasing incidence increases age. Currently, prognosis assessed using International Prognostic Index. In recent years, in European regions, there has been a significant improvement survival DLBCL due to addition rituximab standard chemotherapy (CHOP protocol). However, despite advances treatment, long-term remission only achieved half patients. Laryngeal lesions this...
To reveal clinical and immunological features of bronchial asthma (BA) combined with thyroid gland pathology, sixty patients have been examined in five equal groups, i.e., BA; hypothyroidism; thyrotoxicosis; BA + thyrotoxicosis. We assessed serum IgE, IgG levels, as wekk IL-4/IFNγ, IL-4/IL-1, IL-1/IL-6 ratios. Clinical exacerbations were observed more frequently hypothyroidism, compared patients. Remissions prolonged patients, than groups or hyperthyroidism. Serum IgE levels much increased...
Primary cutaneous lymphomas are a group of extranodal B-cell non-Hodgkins lymphomas. diffuse B-large cell lymphoma, leg-type, is an extremely rare and aggressive variant primary lymphoma. Due to the contradictory nature, poor prognosis, high frequency recurrence this disease, treatment patients multidisciplinary, based on accurate histological immunohistochemical classification as well risk factor assessment. In report, we present clinical case skin with positive response chemotherapy.
...
ПЭТ-ОТВЕТ КАК ПРЕДИКТОР ВЫЖИВАЕМОСТИ У ПАЦИЕНТОВ С ПЕРВИЧНОЙ МЕДИАСТИНАЛЬНОЙ В-КРУПНОКЛЕТОЧНОЙ ЛИМФОМОЙКамаева И.А., Лысенко И
Purpose of the study to summarize available data on methods for creating bladder cancer models their application in preclinical studies. Material and methods. A systematic literature search was conducted Elibrary, Pubmed, Googlescholar, CyberLeninka databases. Results. The review shows current various practice. Bladder pathology, identification diagnostic markers development new therapies are main challenges facing management cancer. To solve these problems, it is often necessary conduct...
Background: Primary mediastinal large B-cell lymphoma (PMBCL) is a type of aggressive which affects mainly young patients and characterized by local spread development tumor conglomerate in the mediastinum. One most important pathogenetic mechanisms PMBCLs their genetic heterogenety. There are lot similarities between molecular profiles diffuse lymphoma, Hodgkin’s gray zone described literature. However, there no clear molecular-genetic characteristic PMBCL. Despite successful treatment with...
e19564 Background: Patients with non-Hodgkin's lymphomas (NHL) develop abnormalities in the structural and functional organization of immune system leading to deficiency. Chemotherapy (CT) patients after SARS-CoV infection is associated a more severe disease course affecting treatment results. The cytokine-producing activity (CPA) blood cells poorly studied, while it determines effectiveness antitumor anti-infective functions system. purpose this study was evaluate CPA peripheral mononuclear...
e19554 Background: The purpose of this study was to assess NT-proBNP as a marker renal dysfunction in patients with diffuse large B-cell lymphoma receiving immune polychemotherapy. Methods: involved 24 aged 23-69 years (median 57 years) primary diagnosis (DLBCL). status assessed by the blood serum levels creatinine, urea, (Vitros 5600, USA), sodium (Cobas b221, Switzerland) calculation glomerular filtration rate (GFR) according CKD-EPI formula, well urine albumin Integra 400 plus,...
e19520 Background: The purpose of this study was to compare morphological and immunophenotypic characteristics the tumor population B-lymphocytes with varying restrictions immunoglobulin light chains in patients chronic lymphocytic leukemia (CLL). Methods: We examined 30 CLL (median age 64.9±8.6 years). All underwent CBC+DIFF blood tests (Sysmex XE 2100, Japan), examinations (BioVision; Micros, Austria), immunophenotyping (IPT) by multicolor flow cytometry (Navios 10/3, Beckman Coulter, USA)...
Hodgkin's lymphoma is a malignant disease of the lymphatic system. was first described by Dr. Thomas Hodgkin in 1832 and later named “Hodgkin's disease” Samuel Wilkes. accounts for about 24 % all lymphomas. classified as classical nodular lymphoid-predominant (Nodular type lymphoidpredominant lymphoma). Classical includes following histologic variants: sclerosis variant (types I II), mixed cell variant, classic lymphocyte-rich rare lymphoid depletion variant. Epidemiological serological...
e19572 Background: The development of lymphomas is accompanied by disorders in the structural and functional organization immune system leading to deficiency. Such patients are at greater risk severe SARS-CoV infection. Our purpose was assess parameters cellular immunity with a history multi-course chemotherapy, therapy anti-CD20+ antibodies PCR-confirmed COVID19. Methods: study included 12 adult lymphoproliferative diseases (non-Hodgkin's large B-cell (NHL) - 7, Hodgkin's (HL) 5) COVID-19....